Probiotics, prebiotics and synbiotics in the treatment of inflammatory bowel disease - A systematic review;Probiotyki, prebiotyki i synbiotyki w leczeniu nieswoistych zapaleń jelit - Przelad systematyczny

Pediatria Wspolczesna

Volumn 9, Issue 4, 2007, Pages 266-275

  Szajewska, Hanna ^a   Horvath, Andrea ^a   Dziechciarz, Piotr ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Crohn's disease; Microbiota; Microflora; Ulcerative colitis

Indexed keywords

MESALAZINE; PREBIOTIC AGENT; PROBIOTIC AGENT;

BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BREVE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; ESCHERICHIA COLI; EVIDENCE BASED MEDICINE; HUMAN; ILEITIS; INTESTINE SURGERY; LACTOBACILLUS; MEDICAL RESEARCH; MEDLINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SACCHAROMYCES BOULARDII; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 38049173080     PISSN: 15075532     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Hugot J.P., Chamaillard M., Zouali H. i wsp.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 2001, 411, 599-603.
2. Hisamatsu T., Suzuki M., Reinecker H.C. i wsp.: CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology, 2003, 124, 993-1000.
3. Kobayashi K.S., Chamaillard M., Ogura Y. i wsp.: NOD2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science, 2005, 307, 731-734.
4. Netea M.G., Kullberg B.J., de Jong D.J. i wsp.: NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur. J. Immunol., 2004, 34, 2052-2059.
5. Standyk A.W.: Intestinal epithelial cells as a source of inflammatory cytokines and chemokines. Can. J. Gastroenterol., 2002, 16, 241-246.
6. Kwon J.H., Keates S., Bassani L. i wsp.: Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut, 2002, 51, 818-826.
7. Swidsinski A., Ladhoff A., Pernthaler A. i wsp.: Mucosal flora in inflammatory bowel disease. Gastroenterology, 2002, 122, 44-54.
8. Seksik P., Rigottier-Gois L., Gramet G. i wsp.: Alternations of the dominant faecal bacterial groups in patients with Crohn's disease of colon. Gut, 2003, 52, 237-242.
9. Sartor R.B.: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology, 2004, 126, 1620-1633.
10. Joint FAO/WHO Working Group: Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, April 30 and May 1, 2002.
11. Holzapfel W., Geisen P., Bjorkroth J., Schillinger U.: Taxonomy and important features of probiotic microorganisms in food and nutrition. Am. J. Clin. Nutr., 2001, 73, supl., 365S-73S.
12. Sarem-Damerdjii L.O., Sarem F., Marchall L.: In vitro colonization ability of human colon mucosa by exogenous Lactobacilus strains. FEMS Microbiol. Lett., 1995, 131, 133-137.
13. Silva M., Jacobus N.V., Deneke C.: Antimicrobial substance from a human Lactobacillus strain. Agents Chemother., 1987, 31, 1231-1233.
14. Wilson K.H., Perini I.: Role of competition for nutrients in suppresion of Clostridium difficile by colonic mikroflora. Infect. Immun., 1988, 56, 2610-2614.
15. Vanderbergh P.A.A.: Lactic acid bacteria, their metabolic products and interference with microbal growth. FEMS Microbiol. Rev., 1993, 12, 221-238.
16. Pothoulakis C., Kelly C.P., Joshi M.A.: Sacharomyces boulardii inhibits Clostridium difficile toxin A blinding and enterotoxicity in rat ileum. Gastroenterology, 1993, 104, 1108-1115.
17. Perdigon G., De Macias M.E.N., Alvarez S.: Effect of perorally administred lactobacilli on macrophage activation in mice. Infect. Immun., 1986, 53, 404-410.
18. Isolauri E., Joensuu J., Suomalainem H.: Improved immunogenicity of oral Dx RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine, 1995, 13, 310-312.
19. De Simone C.: The role of probiotics in modulation of the immune system in man and in animals. Int. J. Immunother., 1993, 1, 23-28.
20. Mack D.R., Michail S., Wei S.: Probiotics inhibit gastropatogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am. J. Physiol., 1999, 276, 941-950.
21. Ewaschuk J.B., Walker J.W., Diaz H., Madsen K.L.: Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J. Nutr., 2006, 136, 1483-1487.
22. Szajewska H., Setty M., Mrukowicz J., Guandalini S.: Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J. Pediatr. Gastroenterol. Nutr., 2006, 42, 454-475.
23. Gibson G.R., Probert H.M., Van Loo J. i wsp.: Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nurt. Res. Rev., 2004, 17, 259-275.
24. Macfarlane S., Macfarlane G.T., Cummings J.H.: Review article: prebiotics in the gastrointestinal tract. Aliment. Pharmacol. Ther., 2006, 24, 701-714.
25. Słownik podstawowych pojeć. Medycyna Praktyczna - Pediatria, 2005, 4, 81-84.
26. Guyatt G., Rennie D. (red.): Users' guides to the medical literature. American Medical Association, 2002.
27. Higgins J.P.T., Green S. (red.): Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (popr. maj 2005). [w:] The Cochrane Library, cz. 3, John Wiley & Sons, Chichester, UK Ltd. 2005.
28. Alderson P., Green S., Higgins J.P.T. (red.): Cochrane Reviewers' Handbook 4.2.2 (popr. marzec 2004). [w:] The Cochrane Library, cz. 1, 2004
29. Rolfe V.E., Fortun P.J., Hawkey C.J. i wsp.: Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev., 2006, 4, CD004826.
30. Bousvaros A., Guandalini S., Baldassano R.N. i wsp.: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis., 2005, 11, 833-839.
31. Campieri M., Rizzello F., Venturi A. i wsp.: Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrance of Crohn's disease: a randomized controlled study versus mezalamine. Gastroenterology, 2000, 118, supl. 2, A781.
32. Guslandi M., Mezzi G., Sorghi M., Testoni P.A.: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci., 2000, 45, 1462-1464.
33. Malchow H.A.: Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J. Clin. Gastroenterol., 1997, 25, 653-658.
34. Prantera C., Scribano M.L., Falasco G. i wsp.: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut, 2002, 51, 405-409.
35. Schultz M., Timmer A., Herfarth H.H. i wsp.: Laclobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol., 2004, 4, 5.
36. Zocco M.A., Zileri Dal Verme L., Armuzzi A. i wsp.: Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease. Gastroenterology, 2003, 124, supl. 1, A201.
37. Marteau P., Lemann M., Seksik P. i wsp.: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut, 2006, 55, 842-847.
38. Van Gossum A., Dewit O., Louis E. i wsp.: Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after Ileo-caecal resection. Inflamm. Bowel Dis., 2007, 13, 135-142.
39. Kruis W., Schütz E., Fric F. i wsp.: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther., 1997, 11, 853-858.
40. Rembacken B.J., Snelling A.M., Hawkey P.M. i wsp.: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet, 1999, 354, 635-639.
41. Kruis W., Fric F., Pokrotnieks J. i wsp.: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, 53, 1617-1623.
42. Ishikawa H., Akedo I., Umesaki Y. i wsp.: Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J. Am. Coll. Nutr., 2003, 22, 56-63.
43. Zocco M.A., dal Verme L.Z., Cremonini F. i wsp.: Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther., 2006, 23, 1567-1574.
44. Kato K., Mizuno S., Umesaki Y. i wsp.: Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther., 2004, 20, 1133-1141.
45. Tursi A., Brandimarte G., Giorgetti G.M. i wsp.: Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med. Sci. Monit., 2004, 10, PI126-131.
46. Mimura T., Rizzello F., Helwig U. i wsp.: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut, 2004, 53, 108-114
47. Gionchetti P., Rizzello F., Helwig U. i wsp.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology, 2003, 124, 1202-1209.
48. Gionchetti P., Rizzello F., Venturi A. i wsp.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology, 2000, 119, 305-309.
49. Kuisma J., Mentula S., Jarvinen H. i wsp.: Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment. Pharmacol. Ther., 2003, 17, 509-515.
50. Fernandez-Banares F., Hinojosa J., Sanchez-Lombrana J.L. i wsp.: Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am. J. Gastroenterol., 1999, 94, 427-433.
51. Welters C.F., Heineman E., Thunnissen F.B. i wsp.: Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis. Colon Rectum, 2002, 45, 621-627.
52. Furrie E., Macfarlane S., Kennedy A. i wsp.: Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut, 2005, 54, 242-249.
53. Chermesh I., Tamir A., Reshef R. i wsp.: Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig. Dis. Sci., 2007, 52, 385-389.
54. Marteau P.R., de Vrese M., Cellier C.J. i wsp.: Protection from gastrointestinal diseases with the use of probiotics. Am. J. Clin. Nutr., 2001, 73, supl., 430S-36S.
55. Bernardeau M., Vernoux J.P., Gueguen M.: Safety and efficacy of probiotic lactobacilli in promoting growth in post-weaning Swiss mice. Int. J. Food Microbiol., 2002, 77, 19-27.
56. Rachmilewitz D., Karmeli F., Takabayashi K. i wsp.: Amelioration of experimental colitis by probiotics is due to the immunostimulatory effect of its DNA. Gastroenterology, 2002, 122, abstr. T1004.
57. Madsen K., Jijon H., Yeung H. i wsp.: DNA from probiotic bacteria exerts anti-inflammatory actions on epithelial cells by inhibition of NF κB. Gastroenterology, 2002, 122, abstr. 546.
58. Santor R.B.: Probiotic therapy of intestinal inflammation and infections. Curr. Opin. Gastroemerol., 2004, 21, 44-50.
59. Bibiloni R., Fedorak R.N., Tannock G.W. i wsp.: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol., 2005, 100, 1539-1546.
60. Venturi A., Gionchetti P., Rizzello F. i wsp.: Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther., 1999, 13, 1103-1108.
61. Guslandi M., Giollo P., Teston! P.A.: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol., 2003, 15, 697-698.
62. Hanai H., Kanauchi O., Mitsuyama K. i wsp.: Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int. J. Mol. Med., 2004, 13, 643-647.
63. Ulisse S., Gionchetti P., D'Alo S. i wsp.: Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am. J. Gastroenterol., 2001, 96, 2691-2699.
64. Kanauchi O., Mitsuyama K., Homma T. i wsp.: Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int. J. Mol. Med., 2003, 12, 701-704.
65. Kuhbacher T., Ott S.J., Helwig U. i wsp.: Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut, 2006, 55, 833-841.
66. Laake K.O., Line P.D., Grzyb K. i wsp.: Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a I-configurated ileal-pouch-analanastomosis (IPAA). Scand. J. Gastroenterol., 2004, 39, 1228-1235.
67. Laake K.O., Bjorneklett A., Aamodt G. i wsp.: Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand. J. Gastroenterol., 2005, 40, 43-51.
68. Lindsay J.O., Whelan K., Stagg A.J. i wsp.: Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut, 2006, 55, 348-355.
69. Suzuki A., Mitsuyama K., Koga H. i wsp.: Bilidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrition, 2006, 22, 76-81.
70. Shibata C., Funayama Y., Fukushima K. i wsp.: Effect of calcium polycarbophil on bowel function after restorative proctocolectomy for ulcerative colitis: a randomized controlled trial. Dig. Dis. Sci., 2007, 52, 1423-1426.